Gastrointestinal obstruction is a common problem in advanced malignant disease, but its management remains controversial. In those patients for whom surgery is not appropriate, medical intervention is the only remaining option. We present a series of 14 patients with intestinal obstruction who were managed with subcutaneous injections of octreotide, a somatostatin analogue which reduces the volume of gastrointestinal secretions. Good control of vomiting was achieved in 12 patients, and no major side effects were observed. Octreotide would appear to be a useful drug in this clinical situation
Background: Somatostatin has an inhibitory effect on the endocrine and exocrine secretions of the gu...
Context Somatostatin analogues are commonly used to relieve symptoms in malignant bowel obstruction ...
Objective. To provide an overview of the role of octreotide for managing symptoms in oncology and pa...
In the case of malignant intestinal obstruction, surgery often carries important mortality and morbi...
Intestinal obstruction is a common and distressing clinical complication in ovarian cancer. The aim ...
Objective: In patients with advanced cancer, malignant bowel obstruction (MBO) causes gastrointestin...
Octreotide in the management of intestinal obstruction in terminal cancer patients
In advanced cancer patients with inoperable bowel obstruction, the administration of antisecretive a...
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer...
Malignant bowel obstruction and intractable diarrhea in advanced cancer are common devastating syndr...
Following gastric surgery, 25-50% of patients experience dumping symptoms. Early dumping usually inv...
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancer...
Context Does octreotide reduce vomiting in cancer-associated bowel obstruction? Objectives To evalua...
AbstractContextDoes octreotide reduce vomiting in cancer-associated bowel obstruction?ObjectivesTo e...
Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine b...
Background: Somatostatin has an inhibitory effect on the endocrine and exocrine secretions of the gu...
Context Somatostatin analogues are commonly used to relieve symptoms in malignant bowel obstruction ...
Objective. To provide an overview of the role of octreotide for managing symptoms in oncology and pa...
In the case of malignant intestinal obstruction, surgery often carries important mortality and morbi...
Intestinal obstruction is a common and distressing clinical complication in ovarian cancer. The aim ...
Objective: In patients with advanced cancer, malignant bowel obstruction (MBO) causes gastrointestin...
Octreotide in the management of intestinal obstruction in terminal cancer patients
In advanced cancer patients with inoperable bowel obstruction, the administration of antisecretive a...
Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer...
Malignant bowel obstruction and intractable diarrhea in advanced cancer are common devastating syndr...
Following gastric surgery, 25-50% of patients experience dumping symptoms. Early dumping usually inv...
Octreotide, a somatostatin analogue, has been shown to inhibit the growth of gastrointestinal cancer...
Context Does octreotide reduce vomiting in cancer-associated bowel obstruction? Objectives To evalua...
AbstractContextDoes octreotide reduce vomiting in cancer-associated bowel obstruction?ObjectivesTo e...
Bowel obstruction may be an inoperable complication in patients with end-stage cancer. Scopolamine b...
Background: Somatostatin has an inhibitory effect on the endocrine and exocrine secretions of the gu...
Context Somatostatin analogues are commonly used to relieve symptoms in malignant bowel obstruction ...
Objective. To provide an overview of the role of octreotide for managing symptoms in oncology and pa...